lorazepam has been researched along with Breast Cancer in 7 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 9.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 7.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 5.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 3.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "56 female patients with breast carcinoma and treated with polychemotherapy: adriamycin, vindesine, ciclophosphamide and 5-fluorouracil were studied, divided in three groups with different antiemetic schedule: group A 40 mg/iv of metoclopramide; group B 40 mg iv of metoclopramide and 125 mg/iv of methylprednisolone before beginning chemotherapy; and group C 2 mg/oral of lorazepam, 125 mg/iv methyl-prednisolone and 1 mg/kg/oral of metoclopramide previously to begin chemotherapy; at two and four hours of the first dose, metoclopramide was repeated the same doses (really) three doses each two hours." | 2.67 | [Antiemetic treatments associated with antineoplastic chemotherapy]. ( Guillén Lloveria, G; Mayordomo Cámara, JJ; Sáenz Cusi, A; Sáez Martínez, MJ; Tres Sánchez, A, 1990) |
| "Delirium is still one of the most common and distressing symptoms in palliative care patients." | 1.38 | Reversible delirium in an advanced cancer patient. ( Jagsch, C; Kierner, KA; Watzke, HH, 2012) |
| " The BAD pump was safe and effective in minimizing nausea and vomiting associated with HDC, and thus, eliminated the need for hospitalization for management of chemotherapy-induced nausea and vomiting." | 1.30 | Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. ( Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roden, E | 1 |
| Walder, B | 1 |
| Simões, S | 1 |
| Amorim, J | 1 |
| Machado, A | 1 |
| Kierner, KA | 1 |
| Jagsch, C | 1 |
| Watzke, HH | 1 |
| Climent, MA | 1 |
| Palau, J | 1 |
| Ruiz, A | 1 |
| Soriano, V | 1 |
| Aznar, E | 1 |
| Olmos, T | 1 |
| Guillem, V | 1 |
| Dix, S | 1 |
| Cord, M | 1 |
| Howard, S | 1 |
| Coon, J | 1 |
| Belt, R | 1 |
| Geller, R | 1 |
| Harousseau, JL | 1 |
| Zittoun, R | 1 |
| Bonneterre, J | 1 |
| Hedouin, M | 1 |
| Ouvry, J | 1 |
| Tres Sánchez, A | 1 |
| Sáez Martínez, MJ | 1 |
| Mayordomo Cámara, JJ | 1 |
| Guillén Lloveria, G | 1 |
| Sáenz Cusi, A | 1 |
2 trials available for lorazepam and Breast Cancer
| Article | Year |
|---|---|
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Hemato | 2000 |
[Antiemetic treatments associated with antineoplastic chemotherapy].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1990 |
5 other studies available for lorazepam and Breast Cancer
| Article | Year |
|---|---|
Preoperative evaluation and preparation by anaesthesiologists only, please!
Topics: Ambulatory Surgical Procedures; Anti-Anxiety Agents; Anxiety; Breast Neoplasms; Female; Humans; Lora | 2013 |
Intense lorazepam-induced sexual arousal.
Topics: Breast Neoplasms; Carcinoma; Female; Humans; Lorazepam; Middle Aged; Sexual Dysfunctions, Psychologi | 2010 |
Reversible delirium in an advanced cancer patient.
Topics: Amines; Analgesics; Analgesics, Opioid; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, No | 2012 |
The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; | 1998 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1999 |